英找到癌症要害 引導免疫細胞直攻 2016-03-05 02:48 聯合報 編譯 陳韻涵／報導 英國科學家宣稱找到了癌症的「阿基里斯的腳跟」（要害），未來將可引導免疫細胞根據此種獨特標記去準確攻擊癌細胞，以治療甚至治癒癌症。不過這種量身打造的「革命性」療法可能兩年後才會展開人體試驗，而且十分昂貴。 英國倫敦大學學院（ＵＣＬ）研究人員發現一種方式，能夠識別一種會發生在每一個癌症細胞的頑強突變，且部分肺癌患者的抗病白血球恰好與這些突變完全對應。醫療團隊未來能將這些白血球從病患身上取出，經實驗室培養後，再注射回體內攻擊癌細胞。理論上，這些白血球會殺死所有癌細胞。另一種方式是，利用這些突變資訊來研發訂製疫苗，引導免疫系統對抗癌細胞。新研究結果三日發表在「科學」期刊官網。ＵＣＬ研究團隊認為，既有的癌症疫苗引導免疫細胞去攻擊錯誤的對象，可能是現行疫苗效果不佳的原因。但問題是，癌細胞不是由相似細胞組成，它們隨著時間突變和成長。現行藥物只瞄準某一種細胞，一旦癌細胞變異就會失效；就算藥物能殺死癌細胞，一些高度突變的細胞仍存在病患體內，導致舊疾復發。英國廣播公司解釋，癌細胞像樹一樣成長，卻有著核心「樹幹」突變，但這些突變朝所有方向開枝散葉，這就是癌症的變異性。ＵＣＬ的研究找到發現一種方式，能辨識改變抗原的「樹幹」突變方式。ＵＣＬ癌症研究所史瓦頓教授說：「這令人興奮，現在我們可以優先鎖定每個細胞裡都有的腫瘤抗原，這就是高度複雜癌症的阿基里斯腳跟。這很美好，我們能將客製化藥品發揮到極致，讓每位病患擁有獨特的訂製療法。」客製藥物可能十分昂貴，但現行癌症藥物也不便宜。目前已在使用的新癌症藥物通常要價七萬英鎊（約台幣三百卅一萬元），但只能延壽兩個多月。
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade/ Science 25 Mar 2016/ Vol. 351, Issue 6280, pp. 1463-1469, One contributing factor in antitumor immunity is the repertoire of neoantigens created by genetic mutations within tumor cells. Like the corresponding mutations, these neoantigens show intratumoral heterogeneity. Some are present in all tumor cells (clonal), and others are present in only a fraction of cells (subclonal). In a study of lung cancer and melanoma, McGranahan et al. found that a high burden of clonal tumor neoantigens correlated with improved patient survival, an increased presence of tumor-infiltrating lymphocytes, and a durable response to immunotherapy.
Abstract As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8+ tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non–small cell lung cancer and expressed high levels of PD-1. Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. T cells recognizing clonal neoantigens were detectable in patients with durable clinical benefit. Cytotoxic chemotherapy–induced subclonal neoantigens, contributing to an increased mutational load, were enriched in certain poor responders. These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124-8 Abstract: Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy.
Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy/ December 15, 2015 | Oncology Journal By John P. Finnigan, Jr, BS, Alex Rubinsteyn, PhD, Jeffrey Hammerbacher, BA, and Nina Bhardwaj, MD, PhD Oncology (Williston Park). 29(12):970-972, 974-975. Introduction The ability to leverage the adaptive immune system to treat human cancers has been a goal of immunologists and oncologists dating back to the pioneering experiments of William Coley. The ideal immunotherapy should mobilize the immune system to clear an existing population of malignant cells, without damaging adjacent healthy cells, and remain active in the event of recurrence. In practice, these goals have yet to be fully realized, in part because of the difficulties associated with identifying targets of the antitumor immune response. However, the introduction of highly effective immunotherapeutics—such as immune checkpoint blockade—coupled with advances in gene sequencing, has changed the face of the field entirely. Recent evidence indicates that mutations unique to a given individual's tumor may be the long–sought-after targets of effective antitumor immunity and may hold the key to the design of the next generation of immune-based therapeutics.
Background Descriptions of tumor antigens first appeared in the literature in the middle of the 20th century following observations of immune-mediated clearance of carcinogen-induced tumors in murine experimental models.[1-4] In the subsequent decades many tumor antigens have been identified, including developmental (carcinoembryonic antigen, WT1 [Wilms tumor 1]), lineage-specific (Melan-A/MART-1 [melanoma antigen recognized by T cells 1], prostatic acid phosphatase), and cancer/testis (MAGE-A [melanoma-associated antigens], NY-ESO-1, PRAME [preferentially expressed antigen in melanoma]) antigens, all of which are produced by genes overexpressed by malignant cells.[5] These antigens are easily identifiable and often shared among a cohort of subjects.[6,7] However, they are, by definition, "self" antigens and, like other "self" antigens, subject to immune tolerance.[8-11] Thus, the qualities that make these tumor antigens amenable to study may in turn limit their therapeutic utility.[12-15] Recent advances in genetic sequencing technologies have facilitated the discovery of a new class of tumor antigen derived from somatic mutations, which we have termed mutation-derived tumor antigens (MTAs) but which are also known as neoantigens,or tumor-specific antigens.[16,17] MTAs are the product of nonsynonymous somatic variations randomly acquired by malignant cells as a result of deregulated progression through the cell cycle. Nonsynonymous somatic variations change protein sequence and function, facilitating the acquisition of traits associated with replicative advantage and tissue invasiveness.[18,19] Yet, when a nonsynonymous somatic variant is expressed and the variant sequence translated, the immune system may perceive the variant protein as "foreign" or "nonself" and respond to the cell as though it were infected with a pathogen.[20] Notably, the likelihood of generating MTAs appears to be roughly proportional to the number of somatic mutations present within a given tumor.[21,22] However, the production of MTAs does not depend on the type of somatic variation. MTAs have arisen from substitutions, insertions, and deletions, as well as from larger structural rearrangements, such as duplications, inversions, and translocations. Nor does the production of MTAs depend on the oncologic significance of the instigating mutation. MTAs have arisen from both classic tumor suppressors and oncogenes, as well as from somatic mutations of unknown significance. Finally, the production of MTAs does not appear to depend on clinical characteristics of age, sex, and disease histology. MTAs have been identified in patients with multiple types of solid and hematologic malignancies.[23-37] Evidence from both murine and human studies suggests that MTAs play a significant role in the endogenous adaptive immune response to tumors, as well as the induced adaptive immune response to tumors treated with cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) or programmed death 1 (PD-1) antagonists. Indeed, patients with melanoma or squamous-cell non–small-cell lung cancer who are treated with immune checkpoint blockade appear to stand a greater chance of clinical benefit as the burden of somatic mutations increases.[38-40] Furthermore, patients with tumors deficient in DNA mismatch repair, in which the number of somatic mutations can be multiple orders of magnitude greater than in tumors of comparable origin, also appear to fare significantly better when treated with immune checkpoint blockade.[41] However, prospective trials will be required to establish the utility of MTAs as predictive biomarkers. Given the considerable excitement brought about by these findings, as well as the ongoing development of therapeutic approaches that directly target MTAs, we will consider how these tumor antigens are identified, highlight deficiencies in current processes, and speculate as to how existing methods may be improved through further research.
Identification of MTAs The identification of somatic variations in tumors and, by extension, MTAs relies on the use of high-throughput sequencing (Figure 1).[42-44] Typically, material from both the tumor and a matched normal sample are sequenced in tandem.[45,46] Due to economic and technical considerations, sequencing efforts are restricted to the known protein-coding regions of the genome (exome). However, the use of targeted sequencing panels is not advised because this severely limits the ability to identify novel MTAs. Sequencing experiments designed to identify MTAs are performed at higher coverage depths than are typically encountered in the literature. This is true with regard to the sequencing of tumor material, as well as material derived from matched normal samples. Sequence coverage depth is described in terms of the mean number of reads successfully realigned to targeted loci. However, the process by which the exome is enriched prior to sequencing can result in significant nonuniformity in coverage depth. To achieve acceptable mean coverage across all target loci, a mean sequence coverage depth of 150× may be required for normal samples.[47] When tumor samples are sequenced, coverage depths are typically doubled (300×) to account for additional confounders, including intrinsic tumor heterogeneity and contamination of tumor samples with material from stromal and/or other infiltrating cell types. These and other sources of bias may be reduced even further through random sampling of multiple, distinct regions of the tumor or through sequencing of circulating tumor material (cells, DNA). MTAs are produced when a nonsynonymous somatic variant is expressed and the variant sequence is translated into protein. The targeting of MTAs derived from expressed variants can lead to therapeutic responses in vivo in animal models, but the utility of MTAs derived from nonexpressed variants has not been established.[42-44,48] DNA sequencing can be used to measure sequence variation; however, it does not provide a measure of gene expression. Quantifying expression eliminates nonexpressed variants that can confound downstream analysis. In addition, expression analysis through RNA sequencing, as opposed to array-based methods, directly determines transcript sequence and structure, which mitigates the requirement for accurate annotation of the transcriptome. Unfortunately, because of both biologic and technical variables, it is difficult to provide a general recommendation with regard to target depth for RNA sequencing experiments. However, depths in excess of 50 to 100 million reads per sample can be required to unambiguously resolve the sequence of variant-containing transcripts. The technical details of DNA and RNA sequence analysis are beyond the scope of this article. However, we would like to emphasize that the choice of parameters used in sequence analysis can introduce systematic error into the results of these analyses. To overcome these issues, it is advisable to perform all analyses with extensively vetted combinations of bioinformatics tools.[49] It may also be advisable to use many such vetted combinations and to consider only those results arrived at by consensus.[50,51] The final step in identifying MTAs further refines the list of expressed nonsynonymous variants and eliminates those that are unlikely to be immunologically relevant. This procedure has been the subject of a number of recent reviews and will not be exhaustively detailed here. Fritsch et al, van Buuren et al, Rajasagi et al, and Gubin et al provide comprehensive overviews of the methodology.[52-55] Briefly, computational tools are used to assess the variant protein sequence and to determine whether it will be presented by host major histocompatibility complex (MHC) class I or II molecules—surface receptors required for the initiation of a cellular adaptive immune response. It has been demonstrated that putative MTAs that are predicted to bind to MHC molecules by this method can lead to therapeutic responses in vivo.[42-44] However, the criteria used to make this distinction were developed for the infectious disease setting, and additional studies will be required to formally establish criteria for use in identifying MTAs. Finally, there is an urgent need for new animal models that can be used to evaluate MTA-specific therapeutic approaches in a manner that can be translated into studies performed in humans.
Therapeutic Targeting of MTAs Much remains to be determined regarding the specific dose, schedule, and route of delivery of MTA-targeting immune-based therapeutics and the relative role of CD4- vs CD8-mediated immunity (Figure 2).[48] At present, a number of early-phase clinical trials are assessing MTA-targeting vaccines, and the preliminary results are encouraging.[56] Tumor-lysate–, peptide-, RNA-, and dendritic cell–based vaccine substrates are being studied, but the optimal choice of vaccine adjuvant remains to be determined. Trials currently underway have largely employed certain synthetic toll-like receptor ligands, which have been studied in other vaccination projects. However, adjuvants that target other innate immune pattern recognition receptors, including C-type lectin (CLR), nucleotide-binding oligomerization domain (NOD), RIG-I–like (RLR), and stimulator of interferon genes (STING) receptor pathways, remain viable, unstudied alternatives. The use of stimulatory hematopoietins, such as FMS-like tyrosine kinase 3 ligand and granulocyte-macrophage colony-stimulating factor (sargramostim), should also be considered.[57-59] Evidence suggests that indirect targeting of MTAs through the use of vaccine adjuvants or oncolytic viruses injected or infused in situ or directly into the body of existing tumors may represent yet another approach to the stimulation of an MTA-specific immune response.[60,61] Preclinical work suggests that in situ vaccination may be used as a bridge to formal MTA-targeted vaccination for patients with advanced primary or recurrent disease, thus broadening the range of patient groups who are eligible to receive precision immune-based therapeutics. Finally, it will be important to consider the use of MTA-targeted agents in conjunction with CTLA-4 and PD-1/programmed death ligand 1 antagonists (see Figure 2). Although combination approaches have not been formally tested in humans, preliminary evidence suggests that MTA-targeted approaches can boost existing MTA-specific responses and also provoke MTA-specific responses de novo.[56] Thus, combination therapy may serve as a safe and effective means of overcoming resistance to immune checkpoint blockade.[61]
Conclusion At present much remains to be determined regarding the efficacy of MTA-specific immune-based therapeutics, used individually or in combination with other therapeutics. Generating these data will require innovative prospective trial designs compatible with the degree of subject-to-subject variability inherent to this approach. However, because of the abundance of promising preclinical and early-phase clinical data, many in the field are initiating such trials, making the MTAs an exciting new class of targets in cancer immunotherapy.